Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb – CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts. Show more

Location: 830 Winter Street, Waltham, MA, 02451, United States | Website: https://www.q32bio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

26.47M

52 Wk Range

$1.34 - $53.17

Previous Close

$2.17

Open

$2.21

Volume

1,884,799

Day Range

$2.11 - $2.64

Enterprise Value

-10.89M

Cash

54.83M

Avg Qtr Burn

-13.52M

Insider Ownership

6.54%

Institutional Own.

69.51%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.